drugset / Trial / NCT04961515
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Phase 2
Recruiting
19 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital of Zhejiang University · collabFirst People's Hospital of Hangzhou · collabHuzhou Central Hospital · collabJinhua Central Hospital · collabJinhua People's Hospital · collabSecond Affiliated Hospital of Wenzhou Medical University · collabSir Run Run Shaw Hospital · collabWenzhou Central Hospital · collabYinzhou Hospital Affiliated to Medical School of Ningbo University · collabZhejiang Provincial People's Hospital · collabZhejiang Provincial Tongde Hospital · collab
NaSequentialOpen-labelTreatment
Summary
This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |